Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Recursion plans to present data from this trial at a forthcoming medical conference and intends to submit these data for publication in a peer reviewed scientific journal.

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data Growing interest in AI-powered drug discovery draws some big investors–and regulatory questions ...

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

Boltz 2 helps pharma triage vast molecular libraries, turning compute heavy screening into near real time decisions.

Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...

Recursion intends to submit these data for publication in a peer reviewed scientific journal. Next steps will be guided by regulatory discussions and on-going long term extension study. About REC-994 ...